摘要
盘点2012年肾脏病诊疗领域与其他学科一样精彩纷呈,2012改善全球肾脏疾病预后组织(KDIGO)推出多项指南;在减少蛋白尿、延缓慢性。肾脏病(CKD)进展、肾替代治疗等方面都有很多的证据,当然也有争论,现综述如下,供同道参考。
出处
《临床荟萃》
CAS
2013年第4期361-367,共7页
Clinical Focus
参考文献46
-
1Eknoyan G, Eckardt KU, Kasiske BL, et al. KDIGO Clinical Practice Guideline for Glomerulonephritis [J] Kidney Int, 2012,2(Suppl 2) : 143 -153.
-
2Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury[J]. Nephron Clin Pract, 2012,120(4) : 179-184.
-
3Eknoyan G, Lameire N, Eckardt KU, et al. KDIGO Clinical Practice Guidelinefor Anemia in Chronic Kidney Disease[J]. Kidney International,2012,2(Suppl 2):279-335.
-
4Zeng CH, Le W, Ni Z, et al. A multicenter application and evaluation of the oxford classification of IgA nephropathy in adult chinese patients[J]. Am J Kidney Dis, 2012,60 (5) : 812- 820.
-
5Maeda I, Hayashi T, Sato KK, et al. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy[J]. Nephrol Dial Transplant, 2012,27 (7) :2806-2813.
-
6Tatematsu M, Yasuda Y, Morita Y, et al. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy[J]. Clin Exp Nephrol'2012,16(6) : 883 8891.
-
7Zhang Q, Shi SF, Zhu L, et al. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy[J]. Am J Nephrol,2012,35(4) :312-320.
-
8Cheng J, Zhang X, Tian J, et al. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis[J]. Int J Clin Pract, 2012, 66 (10) :917-923.
-
9Tang SC, Lin M, Tam S, et al. Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study[J]. Nephrol Dial Transplant,2012,27(2) :613-618.
-
10Ros-Ruiz S,Aranda-Lara P,Fern/mdez JC, et al. High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy[J]. Nefrologia, 2012,32 (2) : 187-196.
同被引文献49
-
1陈楠,陈佳韵.重视微量白蛋白尿的筛查与诊治[J].实用医院临床杂志,2005,2(1):17-19. 被引量:26
-
2王妍.日本肾脏学会发表慢性肾脏病诊疗指南[J].日本医学介绍,2007,28(9):429-429. 被引量:4
-
3苏定冯.心血管药理学[M].4版.北京:人民卫生出版社,2011:501-537.
-
4Bell M,Liljestam E, Granath F, et al. Optimal follow-up tim(after continuous renal replacement therapy in actual renafailure patients stratified with the RIFLE criteria[J]. Nephro-Dial Transplant,2005,20(2) :354-360.
-
5Mommsen P,Frink M,Pape HC’et al. Elevated systemic IL-1and neopterin levels are associated with posttraumati(complications among patients with multiple injuries: iprospective cohort study[J]. Injury ,2009 ,40(5) : 528-534.
-
6Molitoris BA, Levin A, Warnock DG, et al. Improvingoutcomes of acute kidney injury: report of an initiative[JG. NatClin Pract Nephrol,2007,3(8) :439-442.
-
7Taber SS,Pasko DA. The epidemiology of drug-induceddisorders: the kidney [J]. Expert Opin Drug Saf, 2008, 7(6):679-690'.
-
8Matsui K, Kamijo-Ikemori A, Sugaya T, et al. Usefulness ofurinary biomarkers in early detection of acute kidney injuryafter cardiac surgery in adults [J]. Circ J,2012,76(1):213-220.
-
9He Z,Lu L, Altmann C,Hoke TS,et al. Interleukin-18 bindingprotein transgenic mice are protected against ischemic acutekidney injury [J]. Am J Physiol Renal Physiol. 2008,295(5):1414-1421.
-
10Pedra JH, Cassel SL,Sutterwala FS. Sensing pathogens anddanger signals by the inflammasome[J]. Curr Opin Immunol,2009,21 (1):10-16.
引证文献9
-
1郭艳英,邢蓓,吉米兰木·麦麦提明,李素丽,古再丽努尔·居来提,依帕尔古丽·艾尼完尔,热比娅古丽·依力哈木,王新玲.乌鲁木齐市某社区白蛋白尿检出率及危险因素分析[J].新疆医学,2021,51(2):159-162.
-
2肖威,汪杨.白细胞介素18在诊断急性肾损伤的应用价值探讨[J].临床荟萃,2013,28(12):1330-1332. 被引量:3
-
3崔炜.他汀类药物与肾脏[J].临床荟萃,2014,29(1):1-4. 被引量:2
-
4朱岫芳,康凯.氯沙坦联合贝那普利治疗肾实质性高血压的疗效分析[J].中国全科医学,2014,17(35):4250-4252. 被引量:29
-
5李建华,赵宏娟,赵广平,甄书青,白玉伟,陈永学.尿白细胞介素18在腹腔热灌注化疗中的表达与血肌酐、尿素氮相关性的探讨[J].临床和实验医学杂志,2016,15(23):2353-2356.
-
6牛娜,董建琴,杜雪平.北京市基层全科医生对慢性肾脏病的认知调查[J].中国全科医学,2017,20(10):1267-1270. 被引量:14
-
7程菊,张维维,陈亮,李强.嘉定区某社区老年人慢性肾脏病知识知晓率调查分析[J].临床医学研究与实践,2019,4(27):16-17.
-
8景晓华,韩艳萍,马艳萍,罗静.血清胆红素与慢性肾小球肾炎患者大量蛋白尿、血浆白蛋白、eGFR的相关性研究[J].宁夏医学杂志,2019,0(5):426-428. 被引量:2
-
9白慧丽.氯沙坦联合贝那普利治疗肾实质性高血压的临床疗效与安全性分析[J].世界最新医学信息文摘,2015,15(68):83-84. 被引量:3
二级引证文献51
-
1金明花.缬沙坦联合他克莫司治疗慢性肾小球肾炎临床效果及安全性[J].华夏医学,2020(3):52-55. 被引量:5
-
2罗兴.氯沙坦、依那普利联合使用治疗肾实质性高血压疗效分析[J].今日健康,2016,15(8):65-65.
-
3林雅慧,刘玉红,王宓,左力.社区高危人群慢性肾脏病患病率及筛查策略研究[J].中国实用内科杂志,2018,38(12):1169-1172. 被引量:9
-
4赵秀敏.脂康颗粒联合阿托伐他汀治疗高脂血症的疗效及安全性[J].临床荟萃,2015,30(3):268-272. 被引量:8
-
5许新博.氯沙坦联合贝那普利治疗肾实质性高血压的疗效分析[J].现代妇女(医学前沿),2015,0(5):6-7.
-
6余璐.贝那普利联合氯沙坦治疗肾实质性高血压的临床效果观察[J].健康导报(医学版),2015,20(7):109-109.
-
7周进超.观察氯沙坦联合贝那普利治疗肾实质性高血压的临床疗效[J].中外女性健康研究,2015,0(14):208-209. 被引量:2
-
8罗会俊,朱淑芳,王小毛,张才友.贝那普利联合氨氯地平治疗难治性高血压的效果分析[J].中国当代医药,2015,22(27):112-114. 被引量:5
-
9李雪琴,宋红英.系统性护理在高血压患者中的应用效果[J].临床合理用药杂志,2015,8(27):174-175.
-
10汤林.氯沙坦联合贝那普利治疗肾实质性高血压的疗效与安全性分析[J].中西医结合心血管病电子杂志,2015,3(15):113-114. 被引量:1
-
1傅淑霞.2010年肾脏疾病主要临床进展[J].临床荟萃,2012,27(5):369-374. 被引量:3
-
2傅淑霞.2010年肾脏疾病主要临床进展[J].临床荟萃,2011,26(8):650-654. 被引量:1
-
3韩贺(综述),邢国兰(审校).补体在IgA肾病发病机制中的研究进展[J].国际泌尿系统杂志,2011,31(2):242-246. 被引量:1
-
4白寿军,张永,李彩霞,徐钢,刘晓城.曲尼司特联合缬沙坦治疗难治性IgA肾病的临床研究[J].山东医药,2009,49(33):75-76. 被引量:1
-
5欧俊(综述),尹友生(审校).血小板活化因子与IgA肾病[J].国际泌尿系统杂志,2010,30(3):415-417.
-
6韩文伦,黄朝兴.IgA肾病的研究进展[J].国际泌尿系统杂志,2006,26(2):280-282. 被引量:1
-
7王少华,张红霞,卢志远,张建春.中西医结合治疗IgA肾病150例[J].河北中医,2012,34(10):1502-1503. 被引量:2
-
8宋光周,连耀国.黄葵胶囊为主治疗IgA肾病20例[J].新中医,2005,37(4):78-78. 被引量:7
-
9陈喜生.吗替麦考酚酯联合雷公藤多甙治疗IgA肾病的临床疗效观察[J].医学临床研究,2011,28(7):1295-1296. 被引量:8
-
10吴邱保.中西医结合治疗IgA肾病23例疗效观察[J].广东医学院学报,2006,24(2):181-182.